Evaluating only Translate Bio’s profile at its peak — without knowing the outcome — the model ranked Unit economics as the #1 likely cause. Documented cause: Product failure.
Key Events Timeline
FOUNDING
Translate Bio founded in Lexington, MA to develop mRNA-based therapies for pulmonary and genetic diseases.
FUNDING
IPO raises $84M; partnership with Sanofi announced worth up to $805M for infectious disease mRNA vaccines.
PRODUCT LAUNCH
MRT5005 Phase 1/2 data shows no statistically significant FEV1 improvement in cystic fibrosis patients.
ACQUISITION ATTEMPT
Sanofi acquires Translate Bio for $3.2B but discontinues CF program in 2022; original mission abandoned.
Full Analysis
Free · no account needed
Documented cause
Translate Bio, an mRNA therapeutics company focused on cystic fibrosis with $190M raised, was acquired by Sanofi for $3.2B in August 2021 — but only for its mRNA platform technology, not its lead pulmonary program MRT5005 which had shown disappointing Phase 1/2 results in CF patients. The inhaled mRNA therapy failed to achieve statistically significant improvements in lung function (FEV1), and Sanofi discontinued the CF program entirely in 2022, effectively ending Translate Bio's original mission.
Lesson
“Platform acqui-hires can mask clinical failure; technology value ≠ therapeutic validation.”